Does perioperative use of aprotinin reduce the rejection rate in heart transplant recipients?

[1]  P. Schirmacher,et al.  Inducible NO synthase expression in endomyocardial biopsies after heart transplantation in relation to the postoperative course. , 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[2]  F. Mohr,et al.  Reducing ischemia-reperfusion injury in clinical lung transplantation. , 2007, Transplantation proceedings.

[3]  Marshall I Hertz,et al.  Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  Keyvan Karkouti,et al.  A propensity score case‐control comparison of aprotinin and tranexamic acid in high‐transfusion‐risk cardiac surgery , 2006, Transfusion.

[5]  T. Kuntze,et al.  Aprotinin decreases reperfusion injury and allograft dysfunction in clinical lung transplantation. , 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[6]  M. Pasque,et al.  Blood transfusions decrease the incidence of acute rejection in cardiac allograft recipients. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  M. Goddard,et al.  Endothelial activation in the transplanted human heart from organ retrieval to 3 months after transplantation: an observational study. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  T. Treasure,et al.  Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials , 2005 .

[9]  Silviu Itescu,et al.  Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  L. Mestroni,et al.  Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. , 2004, Circulation.

[11]  L. Mestroni,et al.  Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. , 2004, Circulation.

[12]  A. Laupacis,et al.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. , 2001, The Cochrane database of systematic reviews.

[13]  V. Starnes,et al.  Addition of aprotinin to organ preservation solutions decreases lung reperfusion injury. , 1998, The Annals of thoracic surgery.

[14]  T. Spray.  Use of aprotinin in pediatric organ transplantation. , 1998, The Annals of thoracic surgery.

[15]  H. Eisen,et al.  Defining the role of aprotinin in heart transplantation. , 1996, The Annals of thoracic surgery.

[16]  D. Royston.  Aprotinin therapy in heart and heart-lung transplantation. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[17]  R. Goldfarb,et al.  Induction of DNA synthesis in isolated nuclei by cytoplasmic factors: inhibition by protease inhibitors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.